Pelago: Revolutionizing Substance Use Management

Pelago, a digital clinic partner for U.S. businesses and health plans, secures $58 million in Series C funding to expand its innovative substance use management program. Led by CEO Yusuf Sherwani, Pelago offers personalized support for tobacco, alcohol, and opioid use disorders, with a focus on delivering improved outcomes and ROI. The company's 100% fees-at-risk model has shown significant cost savings and a 3x ROI, making it a game-changer in the healthcare industry. With plans to accelerate its product roadmap and clinical research efforts, Pelago is on a mission to provide accessible and effective substance use care to all, without the stigma typically associated with addiction.